Drug Repurposing for Rare Diseases

Publication date

2021-04

Authors

Roessler, Helen I
Knoers, Nine V.ISNI 0000000392114488
Van Haelst, Mieke M.ISNI 0000000392719356
Van Haaften, GijsORCID 0000-0003-3033-0329ISNI 0000000396383490

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

Currently, there are about 7000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases. Although drug repurposing is not novel, new strategies have been developed in recent years to do it in a systematic and rational way. Here, we review applied methodologies, recent accomplished progress, and the challenges associated in drug repurposing for rare diseases.

Keywords

drug discovery, drug repositioning, drug repurposing, genetic diseases, rare diseases, Taverne, Toxicology, Pharmacology

Citation

Roessler, H I, Knoers, N V A M, van Haelst, M M & van Haaften, G 2021, 'Drug Repurposing for Rare Diseases', Trends in Pharmacological Sciences, vol. 42, no. 4, pp. 255-267. https://doi.org/10.1016/j.tips.2021.01.003